HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 10, October 2018 – Next-generation biosensors - Transforming the delivery of healthcare       » China tops world in alcohol-related deaths       » First China-developed drug for colorectal cancer approved in China       » World's first shrimp genome may reveal why females are superior       » Tetris-like program could speed breast cancer detection       » Wearable patch to monitor blood pressure inside body      
INSIDE INDUSTRY
Globavir announces partnership with Singhealth Duke-NUS Academic Medical Centre to study dengue treatment
Newly established Viral Research and Experimental Medicine Centre (ViREMiCS) will conduct research for the treatment of dengue and chikungunya.

Globavir Biosciences, Inc., a biotechnology company developing therapeutics and diagnostics for infectious diseases, announced a partnership with the SingHealth Duke-NUS Academic Medical Centre (AMC) in Singapore, through its newly established Viral Research and Experimental Medicine Centre (ViREMiCS), to conduct research for the treatment of dengue and chikungunya.

The partnership is the result of a July 2017 Memorandum of Understanding that aims to complete the initial evaluation and clinical evaluation - with the objective of gaining approval - for Globavir's proprietary compound, GBV 006, in Singapore.

Under the terms of the collaboration agreement, ViREMiCS will coordinate the potential dengue clinical trial in Singapore and further research and development efforts for Globavir's drug in the treatment of chikungunya.

GBV 006 is a combination of two orally available small molecule drugs, and has been evaluated and tested extensively in pre-clinical studies for treatment of dengue and other viral illnesses. GBV 006 is developed based on research done at Stanford University, and Globavir has an exclusive worldwide rights to the intellectual property covering GBV 006.

"Dengue remains a significant healthcare problem in many parts of the world, and there is still no treatment available," said Globavir CEO Dr. Shalabh Gupta. "Our partnership with the SingHealth Duke-NUS AMC gives us the opportunity to run clinical trials in an organization that has expertise in running clinical trials for dengue as well as the infrastructure to recruit and monitor these patients, not just for initial trials but also for late stage clinical trials.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy